GeneCentric’s core product is GenomicsNext, an integrated liquid biopsy platform that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from ctDNA. The company’s ExpressCT technology measures gene expression using information embedded in ctDNA and underpins GenomicsNext’s expanded biomarker coverage. GeneCentric has a pipeline of predictive response signatures and uses AI-based tools and its rT(I)ME Explorer platform to identify responder populations for oncology therapeutics. The company plans to make GenomicsNext commercially available as a research tool for biopharmaceutical companies in 2025 and to apply the platform to accelerate its predictive-signature pipeline. GeneCentric commercializes its technology through strategic collaborations with biopharma and diagnostics companies across preclinical, clinical development, and commercialization phases. The company is based in Durham, North Carolina, and says the financing will support commercialization and broader deployment of its platform. GeneCentric Therapeutics develops RNA-based diagnostics and predictive response signatures to improve patient selection for oncology therapeutics. Its proprietary RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform has been built over the past decade to discover and develop signatures of responder populations. The company commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics partners across preclinical testing, clinical development and commercialization phases. GeneCentric is expanding its pipeline of predictive response signatures across multiple tumor types and exploring rational combination strategies for targeted and immuno-oncology agents. Proceeds from the recent financing will be used to commercialize its gene signatures and accelerate growth of its predictive signature pipeline. The company is based in Durham, North Carolina. GeneCentric Diagnostics was formed in June and is focused on developing and commercializing novel molecular diagnostic tests to help oncologists and patients make individualized treatment decisions. The company was co-founded this year by Dr. Myla Lai-Goldman, Dr. Neil Hayes and Dr. Chuck Perou; Lai-Goldman serves as CEO. Securities filings show the company has raised $250,000. Hatteras Venture Partners’ website describes GeneCentric as operating in the emerging personalized medicine space. Hayes and Perou are leading UNC genomic cancer research supported by a Cancer Genome Atlas grant that could provide UNC up to $20 million over five years, which may be relevant to GeneCentric’s work. Lai-Goldman is a former LabCorp executive and a venture partner at Hatteras with prior experience co-founding diagnostics companies.

Total raised

$16M

Funding rounds

3

Latest round

Series C

Latest activity

Jun 2025